IDEXX Laboratories (IDXX) Expected to Announce Earnings on Monday

IDEXX Laboratories (NASDAQ:IDXX) is projected to issue its Q3 2026 results before the market opens on Monday, November 2nd. Analysts expect the company to announce earnings of $3.72 per share and revenue of $1.19 billion for the quarter. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. Individuals can find conference call details on the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Monday, November 2, 2026 at 8:30 AM ET.

IDEXX Laboratories (NASDAQ:IDXX) last announced its earnings results on Tuesday, August 4th. The company reported $4.27 EPS for the quarter, beating the consensus estimate of $3.94 by $0.33. IDEXX Laboratories had a return on equity of 71.96% and a net margin of 25.03%. The business had revenue of $1.22 billion for the quarter, compared to analysts’ expectations of $1.20 billion. During the same period in the prior year, the business posted $3.50 earnings per share. The firm’s revenue was up 9.7% on a year-over-year basis. On average, analysts expect IDEXX Laboratories to post $14.81 EPS for the current fiscal year and $16.61 EPS for the next fiscal year.

IDEXX Laboratories Stock Performance

Shares of IDXX stock opened at $560.38 on Monday. The stock has a market capitalization of $44.15 billion, a PE ratio of 39.41 and a beta of 1.55. The business’s 50 day simple moving average is $532.69 and its 200 day simple moving average is $551.46. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.17 and a quick ratio of 0.87. IDEXX Laboratories has a one year low of $500.61 and a one year high of $769.98.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on IDXX. UBS Group boosted their price target on shares of IDEXX Laboratories from $620.00 to $670.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 5th. KeyCorp initiated coverage on shares of IDEXX Laboratories in a research report on Monday, October 12th. They set a “sector weight” rating for the company. JPMorgan Chase & Co. lowered their target price on shares of IDEXX Laboratories from $775.00 to $750.00 and set an “overweight” rating for the company in a research note on Friday, October 16th. Weiss Ratings upgraded shares of IDEXX Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a report on Thursday, October 8th. Finally, Barclays cut their price target on shares of IDEXX Laboratories from $800.00 to $710.00 and set an “overweight” rating on the stock in a research report on Tuesday, August 11th. Seven equities research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $744.09.

Insider Buying and Selling

In other IDEXX Laboratories news, Director Lawrence D. Kingsley sold 2,203 shares of IDEXX Laboratories stock in a transaction that occurred on Friday, September 4th. The stock was sold at an average price of $532.08, for a total value of $1,172,172.24. Following the completion of the sale, the director directly owned 9,568 shares in the company, valued at approximately $5,090,941.44. The trade was a 18.72% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.79% of the stock is owned by corporate insiders.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) develops and provides diagnostic, information technology, and related products and services for the animal health and water testing markets. The company primarily serves veterinary practices, helping them diagnose and monitor diseases through laboratory tests, in-clinic analyzers, software, and digital practice-management solutions.

IDEXX’s companion animal offerings include hematology, chemistry, urinalysis, immunodiagnostics, and imaging-related products, along with reference laboratory services and veterinary software.